自身免疫抗体在重症肌无力发生发展的研究进展  

Research progress of autoimmune antibodies in the occurrence and development of myasthenia gravis

作　　者：欧瑞阳 黄雅舒 OU Ruiyang;HUANG Yashu(West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院,四川成都610041

出　　处：《中国实用神经疾病杂志》2024年第6期789-792,共4页Chinese Journal of Practical Nervous Diseases

基　　金：四川省卫生和计划生育委员会科研课题(编号:150161)。

摘　　要：重重症肌无力(MG)是一种以持续、难以恢复、反复发作为特点的慢性疾病,其临床表现为全身或局部的肌肉易感疲劳,严重情况下,可能会出现呼吸困难,甚至导致肌无力危机,对生命构成威胁,MG的发生与自身产生的抗体有密切关系。目前临床上针对有关自身抗体治疗策略正在不断发展,包括使用免疫抑制剂、靶向治疗和其他免疫调节方法等。本文就近年来有关与重症肌无力发病机制相关的几种重要抗体的研究进展作一综述,包括乙酰胆碱受体抗体、兰尼碱受体抗体、连接素抗体、低密度脂蛋白4抗体和肌肉特异性酪氨酸激酶、聚蛋白抗体和皮动蛋白抗体等。希望通过深入研究和了解与重症肌无力发病机制相关的抗体可以更好地理解MG的发病过程,并为寻找新的MG治疗治疗方法提供依据。Myasthenia gravis(MG)is a chronic disease characterized by persistent,difficult to recover,and recurrent attacks,and its clinical manifestations are systemic or local muscle fatigue,and in severe cases,it may be difficult to breathe,and even lead to muscle weakness crisis,posing a threat to life.The occurrence of MG is closely related to the antibodies produced by itself.At present,clinical treatment strategies for auto-antibodies are constantly developing,including the use of immunosuppressive agents,targeted therapy and other immune regulatory methods.This paper reviews the research progress of several important antibodies related to the pathogenesis of myasthenia gravis in recent years,including acetylcholine receptor antibody,ryanodine receptor antibody,titin antibody,low density lipoprotein 4 antibody,muscle-specific tyrosine kinase,polyprotein antibody and cortactin antibody.It is hoped that through in-depth study and understanding of antibodies related to the pathogenesis of myasthenia gravis,we can better understand the pathogenesis of MG and provide a basis for finding a new MG treatment.

关 键 词：重症肌无力 抗乙酰胆碱受体抗体 低密度脂蛋白4抗体 连接素抗体 肌肉特异性酪氨酸激酶 

分 类 号：R746.1[医药卫生—神经病学与精神病学]